HCV conference

Day 1 | Day 2 | Download Brochure 

WEDNESDAY, APRIL 28

12:30 pm Registration


Inhibiting HCV Polymerase (NS5B)

1:30 Chairperson's Opening Remarks

Youssef Bennani, Ph.D., Vice President Drug, Innovation, Research Management, Vertex Pharmaceuticals

1:40 Structure-Based Design of Non-Nucleoside NS5B Inhibitors for the Treatment of HCV     

Francisco Talamas, Ph.D., Associate Director, Virology, Roche Palo Alto

This presentation will describe the approach used to design potent non- nucleoside NS5B inhibitors using crystallographic information. I will also highlight the different strategies that were utilized in the optimization of potency, physical properties and safety issues.

2:10 PSI-7851: Development of a Nucleotide Prodrug for the Treatment of HCV

Michael J. Sofia, Ph.D., Vice President, Chemistry, Pharmasset, Inc.

Nucleosides have been shown to have a number of advantages for the treatment of HCV. These advantages include a high barrier to resistance, broad genotype coverage and the ability to be combined with other direct acting antiviral agents to produce a robust antiviral response. PSI-7851 is a novel nucleotide prodrug designed to produce a high liver to plasma ratio with the goals of increased potency and once a day dosing. The discovery of PSI-7851 and recent clinical results will be described.

2:40 Panel: HCV Combination Therapies

Moderator: Michael J. Sofia, Ph.D., Vice President, Chemistry, Pharmasset, Inc.

 

Panelists:

Richard Colonno, Ph.D., Chief Scientific Officer, Presidio Pharmaceuticals
Nigel Liverton, Ph.D., Distinguished Senior Investigator, External Discovery and Preclinical Sciences, Merck Research Laboratories
Jeffrey McKelvy, M.D., Ph.D., CEO, iTherX

David Wyles, M.D., Assistant Professor, Infectious Diseases, UCSD

  • What patient population will need combination therapy?
  • How will combination therapy be used, as alternatives in first line therapy or as sequential alternatives for treatment failures?
  • How will biomarkers like IL28 influence treatment decisions and use of direct anti-viral combinations?

3:40 Networking Refreshment Break, Poster and Exhibit Viewing


Inhibiting HCV NS5A

4:20 A New Mouse Model for the Study Human Hepatotropic Viruses

Karl-Dimiter Bissig, M.D., Ph.D., Research Associate, Genetics (Inder Verma’s Lab), Salk Institute for Biological Studies

4:50 Discovery and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with Broad-Spectrum Coverage of all HCV Genotypes

Richard Colonno, Ph.D., Chief Scientific Officer, Presidio Pharmaceuticals

HCV NS5A protein plays a critical role in the HCV viral replicative cycle and is an attractive target for antiviral intervention. PPI-461 is a newly discovered inhibitor of HCV NS5A protein that exhibits a preclinical virologic, pharmacokinetic and toxicology profile supportive of advancement into clinical trials. 

Break-Out Discussions

5:20pm Break-out/Roundtable Discussions

Roundtable Topic: What will be the Ultimate HCV Therapy

Moderator: Youssef Bennani, Ph.D., Vice President Drug Innovation, Research Management, Vertex Pharmaceuticals  

• Why is it necessary to remove Interferon from standard of care?
• What is the ultimate combination therapeutic regimen?
• What would be best-possible therapy duration to cure HCV?

Roundtable Topic: Update on Good Animal Models for HCV Infection

Moderator: Karl-Dimiter Bissig, M.D., Ph.D., Research Associate, Genetics (Inder Verma’s Lab), Salk Institute for Biological Studies

• Past: Animal models for HCV research
• Present: Challenges of viral hepatitis that can be addressed in rodent models
• Future: How can we optimize animal models

Roundtable Topic: Cell Culture Models for HCV Infection

Moderator:  Andrew J. Syder, Ph.D., Research Scientist, iTherX Pharmaceuticals, Inc.

• Historical perspective: replicons, pseudoparticles, and HCV
•  Utility and limitations of current system
• State-of-the-art cell culture for HCV

Roundtable Topic: Discovery of New Targets for HCV Therapy

Moderator: Ronald C. Griffith, Ph.D., former Chief Scientific Officer, Genelabs Technologies Inc.

  • Why is the search for new HCV targets necessary?
  • What new mechanisms/inhibitors are emerging now?
  • What would be the ideal profile for triple/quad combination therapy?

 

 

6:30 End of Day


Day 1 | Day 2